1Ebert W, Muley T, Drin GP, et al. Does the assessment of serum mak- ers inpatients with lung cancer aid in the clinical decision making process [J]. Anticancer Res, 1996, 16 (4B) :2161 -2168.
10Ando S, Suzuki M ,Yamamoto N ,et al. The prognostic value of both neu- ron specific enolase (NSE)and Cyfra21-1 in small cell lung cancer[ J ]. Anticancer Res,2004,24(3b) :1941 - 1946.
5Filipski E,King VM,Li X. Host circadian clock as a control point in tumor propression[J]. J Natl Cancer Inst, 2002,94(9) : 690.
6Morris K. New day downs for research on circadian rtythms [J]. Lancet, 1999,353 : 990.
7Focan C. Maker thythms for cancer chronotherapy: form laboratory animals to human heings[J].Invivo, 1995,9 (4) : 283.
8Smaaland R, Sothem RR, Laenm OD, et al, Rhythms in human bone marrow and blood cells[J].Chronobiolint, 2002,19 ( 1 ) : 101.
9Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002,346 (2):85.
10Ichiki M, Gohara R, Rikimara T, et al. Combination chemotherapy with irinotecan and ifosfamide as second line treatment of refractory or sensitive relapsed small cell lung cancer,a phase Ⅱ study[J]. Chemotherapy, 2003,49(4):200.
